CDKN2A (cyclin dependent kinase inhibitor 2A; HGNC:1787, NCBI Gene ID 1029) is a human locus mapped to chromosome band 9p21.3 that encodes alternative reading-frame proteins p16INK4a (156 aa; CDK4/6 inhibitor) & p14ARF (132 aa; MDM2-p53 stabilizer). CDKN2A acts in G1/S retinoblastoma (RB1) checkpoint arrest, MDM2 sequestration & irreversible cellular senescence, together with p16INK4a Protein Structure & Senescence Biology, CDKN2B (Tandem p15INK4b Paralog at 9p21.3), and CDKN1A (p21Cip1/Waf1 CDK Inhibitor Gene). Encodes both p16INK4a (inhibiting CDK4/6-RB1 phosphorylation) and p14ARF (inhibiting MDM2 to stabilize p53) via overlapping reading frames.
Germline LoF causes Familial Atypical Multiple Mole Melanoma-Pancreatic Cancer syndrome; gold-standard biomarker & senolytic target of aging
Gene Structure & Expression
Genomic Organization & Cytogenetic Locus: Extraordinary dual-coding locus at chromosome 9p21.3 that uses two separate promoters and alternative first exons (exon 1-alpha for p16INK4a and exon 1-beta located 20 kb upstream for p14ARF) spliced onto shared exons 2 and 3—which are translated in two completely different, overlapping open reading frames so that p16INK4a (four ankyrin repeats) and p14ARF (arginine-rich nucleolar protein) share zero amino-acid sequence homology.
Cellular & Tissue Expression Profile: Silenced in young proliferating cells by Polycomb Repressive Complexes PRC1 (BMI1) and PRC2 (EZH2/H3K27me3), but progressively derepressed up to 10- to 50-fold across human tissues during chronological aging, telomere attrition, oxidative stress, and oncogenic RAS/RAF signaling (oncogene-induced senescence).
Molecular Function & Pathways
Biochemical & Physiological Mechanism: p16INK4a binds directly to cyclin-dependent kinases CDK4 and CDK6 to block Cyclin D complex assembly and prevent RB1 phosphorylation—locking E2F transcription factors in an inactive complex that enforces irreversible G1 cell-cycle arrest (cellular senescence)—while p14ARF binds the E3 ubiquitin ligase MDM2 and sequesters it inside the nucleolus, stabilizing p53 (TP53) to induce p21 (CDKN1A) or apoptosis.
Clinical & Therapeutic Significance
Human Genetic Variants & Disease Phenotypes: After TP53, CDKN2A is the most frequently inactivated tumor suppressor locus in human cancer (homozygously deleted or promoter-hypermethylated in melanoma, glioblastoma, pancreatic adenocarcinoma, and NSCLC); germline heterozygous mutations cause Familial Atypical Multiple Mole Melanoma (FAMMM) and hereditary pancreatic cancer, while non-coding SNPs in the adjacent 9p21.3 ANRIL lncRNA region are the strongest genome-wide susceptibility locus for coronary artery disease and type 2 diabetes.
Therapeutic & Clinical Pharmacology: Pharmacological mimetics of p16INK4a—the selective CDK4/6 inhibitors palbociclib, ribociclib, and abemaciclib—are standard-of-care therapies in HR+/HER2- breast cancer; conversely, in geroscience, selective clearance of p16INK4a-high senescent cells (via INK-ATTAC/p16-3MR genetic ablation or senolytics such as dasatinib+quercetin and navitoclax) rejuvenates tissue function and extends median lifespan in aged models.